An ongoing dialogue on HIV/AIDS, infectious diseases,
March 25th, 2009
March (Guideline) Madness …
A couple of interesting ID guidelines out this week. For those of you too busy with basketball, here are the relevant links:
- Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities. Identified in 24 states and now found “routinely” in New York and New Jersey, these carbapenem-resistant Enterobacteriaceae (“CPE” is much easier to write and say) are resistant to virtually every available antibiotic. Although these guidelines say that micro labs must do the so-called modified Hodge test (MHT) on enteric gram negatives that have elevated MICs to carbapenems — but still are within the susceptible range — it’s been shown that ertapenem resistance provides a surrogate marker for this carbapenemase production. Nice recent review of the (scary) topic here; quick summary of the guidelines here.
- Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. This massive tome (only 207 pages, 1,391 references) was originally released in an on-line version this past summer at aidsinfo.nih.gov, and I commented on it then in AIDS Clinical Care. It is an absolutely critical resource, so valuable that I’ve referred to it numerous times since then. But to spare you the task of reading through the whole thing again for revisions, I have gone right to the source — one of the people closely involved in putting the guidelines together — and asked him, so what’s changed since the summer? Here’s his answer: “The current published document notes that in HIV-infected adults who need treatment for HBV infection, treatment for both HIV and HBV infections should be initiated regardless of CD4 cell count. For persons who wish to defer HIV therapy, only anti-HBV agents without any HIV-activity should be used. Oh yeah, and some typos were corrected.”
Categories: Health Care, HIV, Infectious Diseases, Misc, Patient Care
Tags: AIDS, aidsinfo nih, antibiotic, antiretrovirals, Carbapenem, Enterobacteriaceae, ertapenem, HIV, hiv therapy, Infectious Diseases, MICs, opportunistic infections in hiv, Patient Care, prevention, prognosis, resistance, surrogate marker, test, treatment
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Endless Recertification in Medicine — Some Thoughts About the Tests We Take
- My Vote for the Weirdest Antibiotic on the Planet
- Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Really Rapid Review — Brisbane IAS 2023
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Arboviral Disease Surveillance in the U.S.
- Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?
- Risk for C. difficile Infection Varies Widely with Choice of Antibiotic
- Mpox in Persons with Previous Infection or Vaccination
- Updated U.S. Guidelines on Opportunistic Infections
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster